Empagliflozin 25 MG: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Empagliflozin 25 MG appears in the FDA drug-label database. Marketed as JARDIANCE.
- Drug class
- Sodium-Glucose Cotransporter 2 Inhibitor (FDA established pharmacologic class)
- Mechanism of action
- Sodium-Glucose Transporter 2 Inhibitors (as stated on the FDA label)
FDA-approved use
JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. ( 1 ) To reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use: Not recommended in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m 2 ( 1 ) Limitations of Use JARDIANCE is not recommended in patients with type 1 diabetes mellitus. It may increase the r…
FDA recalls / enforcement
| Reason (FDA) | Classification | Status | Initiated |
|---|---|---|---|
| Cross Contamination With Other Products: — Boehringer Ingelheim Pharmaceuticals, Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2018-09-04 |
| Labeling: Label Mix-up — Boehringer Ingelheim Pharmaceuticals, Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2023-03-09 |
| CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Cardinal Health Inc. | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2021-03-15 |
| CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions. — CARDINAL HEALTHCARE | Class II (FDA: may cause temporary or reversible harm) | Terminated | 2022-01-26 |
Phase breakdown
Conditions being studied
Recruiting trials involving Empagliflozin 25 MG
- Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes
- EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease
- Empagliflozin in Heart Failure with Reduced Ejection Fraction and End Stage Renal Disease
- SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
- SGLT2i, Hepatic Glucose Production, and SNS
- SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia
- SGLT2i, Pioglitazone, and Ketone Production in T2D
- SGLTi, Hepatic Glucose Production and Ketogenesis
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
- To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
- meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
Common questions
Is Empagliflozin 25 MG FDA-approved?
Yes, marketed as JARDIANCE.
How many recruiting trials involve Empagliflozin 25 MG?
11 recruiting trials across 15 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.